US5256559A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods and compositions for inhibiting platelet aggregation
Assignee: Boston University
•
Filing: 1991-03-27
•
Granted: 1993-10-26
•
Expires: 2011-03-27
Abstract
Abstract This invention relates to anticoagulant and platelet inhibitory compositions, combinations and methods characterized by biologically active peptides which display the anticoagulant and platelet inhibitory activities of hirudin, or analogs thereof, for therapeutic and prophylactic purposes. The methods, compositions and combinations of this invention are advantageously useful for decreasing or preventing platelet aggregation and platelet activation in a patient or a biological sample. These methods, compositions and combinations are particularly useful in patients for whom standard heparin therapy is contraindicated due to a history of heparin-induced thrombocytopenia or an antithrombin III deficiency. This invention also relates to methods, compositions and combinations for treating extracorporeal blood and for increasing platelet storage life.
Inventors
- 👤 John M. Maraganore
- 👤 Joseph A. Jakubowski
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 08:53
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/81; C07K14/815; A; A61; A61K; A61K38/00
Claims Analysis
Total Claims: 27
Claim 1
Independent Claim
143 words
A method for inhibiting platelet aggregation in stored platelets comprisnig the step of storing platelets in the presence of a composition comprising: (a) a pharmaceutically effective amount of a peptide sufficient to inhibit platelet aggregation in stored platelets, said peptide consisting of the formula: Y-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Z, or D-retro forms of said peptide; wherein Y is selected from the group consisting of H, an amino protecting group, Asp, any sequential portion of the amino acid sequence: Val-Thr-Gly-Glu-Gly-Thr-Pro-Lys-Pro-Gln-Ser-His-Asn-Asp-Gly-Asp, said sequential portion comprising at least two C-terminal amino acids of said amino acid sequence; and any sequential portion of the amino acid sequence: Val-Thr-Gly-Glu-Gly-Thr-Pro-Asn-Pro-Glu-Ser-His-Asn-Asn-Gly-Asp, said sequential portion comprising at least two C-terminal amino acids of said amino acid sequence; Z is selected from the group consisting of OH, Leu and Leu-Gln; and the tyrosine residue contains a negatively charged side group; and (b) a pharmaceutically acceptable carrier.
Claim 2
Independent Claim
143 words
A method for inhibiting platelet aggregation in stored platelets comprisnig the step of storing platelets in the presence of a composition comprising: (a) a pharmaceutically effective amount of a peptide sufficient to inhibit platelet aggregation in stored platelets, said peptide consisting of the formula: Y-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Z, or D-retro forms of said peptide; wherein Y is selected from the group consisting of H, an amino protecting group, Asp, any sequential portion of the amino acid sequence: Val-Thr-Gly-Glu-Gly-Thr-Pro-Lys-Pro-Gln-Ser-His-Asn-Asp-Gly-Asp, said sequential portion comprising at least two C-terminal amino acids of said amino acid sequence; and any sequential portion of the amino acid sequence: Val-Thr-Gly-Glu-Gly-Thr-Pro-Asn-Pro-Glu-Ser-His-Asn-Asn-Gly-Asp, said sequential portion comprising at least two C-terminal amino acids of said amino acid sequence; Z is selected from the group consisting of OH, Leu and Leu-Gln; and the tyrosine residue contains a negatively charged side group; and (b) a pharmaceutically acceptable carrier.
Claim 3
Dependent Claim
26 words
The method according to claim 1, wherein the pharmaceutically effective amount of said peptide of part (a) is between about 0.5 μg/ml and about 1,000 μg/ml.
Claim 4
Dependent Claim
23 words
The method according to claim 2, wherein the pharmaceutically effective amount of said peptide is between about 5 μg/ml and about 100 μg/ml.
Claim 5
Independent Claim
148 words
A method of inhibiting platelet aggregation in a patient, said method comprising the step of treating said patient in a pharmaceutically accpetable manner with a composition comprisign: (a) a pharmaceutically effective amount of a peptide sufficient to inhibit platelet aggregation in a patient, said peptide consisting of the formula: Y-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Z, or D-retro forms of said peptide; wherein Y is selected from the group consisting of H, an amino protecting group, Asp, any sequential portion of the amino acid sequence: Val-Thr-Gly-Glu-Gly-Thr-Pro-Lys-Pro-Gln-Ser-His-Asn-Asp-Gly-Asp, said sequential portion comprising at least two C-terminal amino acids of said amino acid sequence; and any sequential portion of the amino acid sequence: Val-Thr-Gly-Glu-Gly-Thr-Pro-Asn-Pro-Glu-Ser-His-Asn-Asn-Gly-Asp, said sequential portion comprising at least two C-terminal amino acids of said amino acid sequence; Z is selected from the group consisting of OH, Leu and Leu-Gln; and the tyrosine residue contains a negatively charged side group; and (b) a pharmaceutically acceptabl carrier.
Claim 6
Independent Claim
148 words
A method of inhibiting platelet aggregation in a patient, said method comprising the step of treating said patient in a pharmaceutically accpetable manner with a composition comprisign: (a) a pharmaceutically effective amount of a peptide sufficient to inhibit platelet aggregation in a patient, said peptide consisting of the formula: Y-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Z, or D-retro forms of said peptide; wherein Y is selected from the group consisting of H, an amino protecting group, Asp, any sequential portion of the amino acid sequence: Val-Thr-Gly-Glu-Gly-Thr-Pro-Lys-Pro-Gln-Ser-His-Asn-Asp-Gly-Asp, said sequential portion comprising at least two C-terminal amino acids of said amino acid sequence; and any sequential portion of the amino acid sequence: Val-Thr-Gly-Glu-Gly-Thr-Pro-Asn-Pro-Glu-Ser-His-Asn-Asn-Gly-Asp, said sequential portion comprising at least two C-terminal amino acids of said amino acid sequence; Z is selected from the group consisting of OH, Leu and Leu-Gln; and the tyrosine residue contains a negatively charged side group; and (b) a pharmaceutically acceptabl carrier.
Claim 7
Independent Claim
29 words
The method according to calim 4, wherein said pharmaceutically effective amount of peptide of part (a) is between about 0.1 mg/kg body weight and about 10 mg/kg body weight.
Claim 8
Independent Claim
29 words
The method according to calim 4, wherein said pharmaceutically effective amount of peptide of part (a) is between about 0.1 mg/kg body weight and about 10 mg/kg body weight.
Claim 9
Independent Claim
26 words
The method according to calim 5, wherein said pharmaceutically effective amount of peptide is betwen about 0.2 mg/kg body weight and about 2 mg/kg body weight.
Claim 10
Independent Claim
26 words
The method according to calim 5, wherein said pharmaceutically effective amount of peptide is betwen about 0.2 mg/kg body weight and about 2 mg/kg body weight.
Claim 11
Independent Claim
23 words
The method according to calim 4, wherein at the time of treatment, said patient is suffering from or has suffered from heparin-induced thrombocytopenia.
Claim 12
Independent Claim
23 words
The method according to calim 4, wherein at the time of treatment, said patient is suffering from or has suffered from heparin-induced thrombocytopenia.
Claim 13
Independent Claim
12 words
The method according to calim 4, wherien said patient is a human.
Claim 14
Independent Claim
12 words
The method according to calim 4, wherien said patient is a human.
Claim 15
Independent Claim
73 words
A method for inhibiting platelet aggreation in stored platelets comprisnig the step of storing platelets in the presence of a compostiion comprising a pharmaceutically effective amount of at least one peptide selected from the group consisting of: (a) peptides characterized by a sequence of amino acids consisting of the formula: Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-X; and (b) D-retro forms of the peptides of (a); wherein X is selected from the group consisting of OH, Leu and Leu-Gln.
Claim 16
Independent Claim
73 words
A method for inhibiting platelet aggreation in stored platelets comprisnig the step of storing platelets in the presence of a compostiion comprising a pharmaceutically effective amount of at least one peptide selected from the group consisting of: (a) peptides characterized by a sequence of amino acids consisting of the formula: Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-X; and (b) D-retro forms of the peptides of (a); wherein X is selected from the group consisting of OH, Leu and Leu-Gln.
Claim 17
Independent Claim
81 words
A method for inhibiting platelet aggregation in a patient comprising the step of treating said patient in a pharmaceutically accpetable manner with a composition comprisign a pharmaceutically acceptable carrier and a pharmaceutically effective amount of at least one peptide selected from the group consisting of: (a) peptides characterized by a sequence of amino acids consisting of the fomrula: Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-X; and (b) D-retro forms of the peptides of (a); wherein X is selected from the group consisting of OH, Leu and Leu-Gln.
Claim 18
Independent Claim
81 words
A method for inhibiting platelet aggregation in a patient comprising the step of treating said patient in a pharmaceutically accpetable manner with a composition comprisign a pharmaceutically acceptable carrier and a pharmaceutically effective amount of at least one peptide selected from the group consisting of: (a) peptides characterized by a sequence of amino acids consisting of the fomrula: Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-X; and (b) D-retro forms of the peptides of (a); wherein X is selected from the group consisting of OH, Leu and Leu-Gln.
Claim 19
Independent Claim
19 words
The method according to calim 10, wherein at the time of treatment, said pateint is suffereing from heparin-induced thrombocytopenia.
Claim 20
Independent Claim
19 words
The method according to calim 10, wherein at the time of treatment, said pateint is suffereing from heparin-induced thrombocytopenia.
Claim 21
Independent Claim
19 words
The method according to calim 10, wherein at the time of treatment, said pateint has suffered from heparin-induced thrombocytopenia.
Claim 22
Independent Claim
19 words
The method according to calim 10, wherein at the time of treatment, said pateint has suffered from heparin-induced thrombocytopenia.
Claim 23
Dependent Claim
14 words
The method according to claim 10 or 11, wherein said patient is a human.
Claim 24
Independent Claim
35 words
The method according to any one of claims 1, 4, 7 or 8, wherien said peptide of (a) is selected from the group consisting of Tyr 63 -O-sulfate-hirudin 3-64 and 3-sulfo-Tyr 63 -hirudin 53-64 .
Claim 25
Dependent Claim
62 words
The method according to claim 1, wherien said composition additionally comprises a pharmaceutically effective amount of a compound sufficient to inhibit platelet aggregation in stored platelets, said compound being selected from the group consisting of metal chelaters, prostaglandins, theophylline, small peptide platelet inhibitors, inhibitors of platelet surface components, antibodies against platelet surface components, analogs thereof which display antiplatelet activity and combinations thereof.
Claim 26
Independent Claim
68 words
The method according to calim 4, wherein said composition additionally comprises a pharmaceutically effective amount of a compuond sufficient to inhibit platelet aggregation in a patient, said compuond being selected from the group consisting of cyclooxygenase inhibitors, small non-peptide platelet inhibitors, prostaglandins, theophylline, small peptide platelet inhibitors, hematopoietic factors, inhibitors of platelet surface components, antibodies against platelet surface components, analogs thereof whcih display antiplatelet activity and combinations thereof.
Claim 27
Independent Claim
68 words
The method according to calim 4, wherein said composition additionally comprises a pharmaceutically effective amount of a compuond sufficient to inhibit platelet aggregation in a patient, said compuond being selected from the group consisting of cyclooxygenase inhibitors, small non-peptide platelet inhibitors, prostaglandins, theophylline, small peptide platelet inhibitors, hematopoietic factors, inhibitors of platelet surface components, antibodies against platelet surface components, analogs thereof whcih display antiplatelet activity and combinations thereof.
References Cited (Backward Citations)
US4654302A
Cited
US4745177A
Cited
EP0158564B1
Cited
US4668662A
Cited
EP0168342B1
Cited
EP0171024B1
Cited
WO1986003517A1
Cited
US4767742A
Cited
EP0193175A2
Cited
EP0200655B1
Cited
US4791100A
Cited
US4683291B1
Cited
US4683291A
Cited
US4702908A
Cited
EP0225633A2
Cited
EP0252854A1
Cited
EP0276014A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-10-25 | 1997-04-26 | 1997-10-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-10-25 | 2001-04-26 | 2001-10-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-10-25 | 2005-04-26 | 2005-10-26 | $7700.00 | Window Closed / Lapsed |